IRD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IRD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Opus Genetics's Enterprise Value is $1.25 Mil. Opus Genetics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-13.59 Mil. Therefore, Opus Genetics's EV-to-FCF for today is -0.09.
The historical rank and industry rank for Opus Genetics's EV-to-FCF or its related term are showing as below:
During the past 5 years, the highest EV-to-FCF of Opus Genetics was 6.12. The lowest was -17.06. And the median was -0.81.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2024-12-11), Opus Genetics's stock price is $1.20. Opus Genetics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.090. Therefore, Opus Genetics's PE Ratio (TTM) for today is At Loss.
The historical data trend for Opus Genetics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Opus Genetics Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
EV-to-FCF | - | -7.98 | -2.38 | 2.16 | -19.48 |
Opus Genetics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
EV-to-FCF | Get a 7-Day Free Trial | 1.44 | -19.48 | -1.02 | 0.15 | 0.17 |
For the Biotechnology subindustry, Opus Genetics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Opus Genetics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Opus Genetics's EV-to-FCF falls into.
Opus Genetics's EV-to-FCF for today is calculated as:
EV-to-FCF | = | Enterprise Value (Today) | / | Free Cash Flow (TTM) |
= | 1.247 | / | -13.59 | |
= | -0.09 |
Opus Genetics's current Enterprise Value is $1.25 Mil.
Opus Genetics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.59 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Opus Genetics (NAS:IRD) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Opus Genetics's PE Ratio (TTM) for today is calculated as:
PE Ratio (TTM) | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 1.20 | / | -1.090 | |
= | At Loss |
Opus Genetics's share price for today is $1.20.
Opus Genetics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.090.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Thank you for viewing the detailed overview of Opus Genetics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
George Magrath | officer: Chief Executive Officer | 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335 |
Ronil A. Patel | officer: SVP, Operations & Bus. Dev. | 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335 |
Mina Sooch | director, officer: President and CEO | 17199 N. LAUREL PARK DRIVE, SUITE 401, LIVONIA MI 48152 |
Manuso James S J | director | 5130 ROUTE 212, WILLOW NY 12495 |
Jay Pepose | director | 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335 |
Susan Benton | director | 3916 VALRICO GROVE DRIVE, VALRICO FL 33594 |
Rabourn Amy Zaremba | officer: VP of Finance | 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335 |
Cam Gallagher | director | 6042 CORNERSTONE CT. WEST, SUITE B, SAN DIEGO CA 92121 |
Alan R Meyer | director | |
Sean Ainsworth | director | 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335 |
Bernhard Hoffmann | officer: VP of Corp. Dev. & Ops & Sec. | 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335 |
Lara Sullivan | director | C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850 |
Ben Gil Price | director | 8297 CHAMPIONS GATE BLVD. #444, CHAMPIONS GATE FL 33896 |
Douglas J Swirsky | officer: President and CFO | C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850 |
Lisa Nolan | officer: Chief Business Officer | 36 ROCKLAND MILLS, ROCKLAND DE 19732 |
From GuruFocus
By Marketwired • 09-30-2024
By GuruFocus Research • 02-08-2024
By Business Wire • 10-23-2024
By GlobeNewswire • 09-06-2024
By Marketwired • 05-03-2024
By GuruFocus News • 11-20-2024
By Marketwired • 09-06-2024
By Marketwired • 10-26-2023
By Marketwired • 05-10-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.